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Abstract
Background: Acute pancreatitis is a severe complication of endoscopic retrograde cholangiopancreatography
(ERCP). Previous meta-analyses have shown that indomethacin effectively prevents this complication; however,
the data are limited. We performed a systematic review and meta-analysis to clarify the applications for rectal
indomethacin.
Methods: A systematic search was performed in June 2016. Human prospective, randomized, placebo-controlled
trials that compared rectally administered indomethacin with a placebo for the prevention of post-ERCP pancreatitis
(PEP) were included. A meta-analysis was performed using a random-effects model to assess the outcomes (PEP) using
Review Manager 5.0.
Results: Seven randomized controlled trials met the inclusion criteria (n = 3013). The overall incidence of
PEP was significantly lower after prophylactic administration of rectal indomethacin than after administration of the
placebo (RR, 0.58, 95% CI, 0.40–0.83; P = 0.004). A subgroup analysis was performed for rectal indomethacin administration
compared to a placebo in high-risk patients (RR, 0.46; 95% CI, 0.32–0.65; P < 0.00001) and average-risk patients (RR, 0.75;
95% CI, 0.46–1.22; P = 0.25) and for administration before ERCP (RR, 0.56; 95% CI, 0.39–0.79; P = 0.001) and after
the procedure (RR, 0.61; 95% CI, 0.26–1.44; P = 0.26).
Conclusions: This meta-analysis indicated that prophylactic rectal indomethacin is not suitable for all patients
undergoing ERCP but it is safe and effective to prevent PEP in high-risk patients. In addition, rectal indomethacin
administration before ERCP is superior to its administration after ERCP for the prevention of PEP.
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Background
Acute pancreatitis is the most common complication after
post-endoscopic retrograde cholangiopancreatography
(ERCP). The incidence rate of post-ERCP pancreatitis
(PEP) ranges between 1.6 and 15.7%, with an overall aver-
age of 3.5% [1]. While most cases of PEP are mild, 10-20%
of patients may develop severe acute pancreatitis with
adverse outcomes and many intractable complications.
Therefore, the social and financial burdens caused by
PEP need to be addressed. One study noted that the
possible pathogenesis of PEP includes both increased
pressure and radiocontrast exposure, which contribute
to injury in the PEP model [2]. However, the detailed
pathogenesis of PEP remains unknown, and no spe-
cific or effective treatment for pancreatitis has been
developed. Numerous factors have been found to be
correlated with the development of PEP, including
patient-related factors, such as an age of less than
50 years, female sex, pancreas divisum, sphincter of
Oddi dysfunction (SOD), a history of recurrent pan-
creatitis (≥2 episodes) or history of PEP, and
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procedure-related factors, such as pancreatic sphinc-
terotomy, precut sphincterotomy, difficult cannulation,
pancreatic duct injection or endoscopist experience [3].
Over the past two decades, many methods have been
used to prevent PEP, including pharmacologic preven-
tion and mechanical-related interventions. Treatment
has been unsatisfactory with the exception of the use of
rectal nonsteroidal anti-inflammatory drugs (NSAIDs)
and prophylactic pancreatic stents. A network meta-
analysis based on existing randomized controlled trials
(RCTs) showed that rectal NSAIDs are one of the most
efficacious agents for preventing PEP [4]. However,
prophylactic stent placement is not cost-effective in pa-
tients at average risk for the development of PEP [5].
NSAIDs, especially indomethacin, are potent inhibitors
of phospholipase A2 activity, which can regulate proin-
flammatory mediators such as prostaglandins, leukotri-
enes and platelet-activating factors in the initial
inflammatory cascade of acute pancreatitis [6]. There-
fore, prophylactic rectal indomethacin administration to
prevent PEP is biologically plausible. A meta-analysis by
Rustagi et al.[7] showed that only the rectal route re-
sulted in a significant benefit for the prevention of PEP
compared to non-rectal administration of indomethacin.
Compared to other methods, rectal indomethacin is less
expensive and easily administered, leading to potential
beneficial effects in PEP.
Recent clinical trials and a large number of meta-
analyses have suggested the promising outcomes of
indomethacin use. The European Society of Gastrointes-
tinal Endoscopy and the Japanese Society of Hepato-
Biliary-Pancreatic Surgery guidelines recommended
routine rectal administration of indomethacin in unse-
lected (both high-risk and average-risk) patients to pre-
vent PEP [8, 9]. However, recent high quality RCTs have
revealed that prophylactic rectal indomethacin did not
reduce the incidence or severity of PEP in consecutive
patients undergoing ERCP [10]. It is necessary to recon-
sider the selection of suitable patients for prophylactic
rectal indomethacin after ERCP. A survey from 29 coun-
tries reported using NSAIDs for PEP prophylaxis was
not widely accepted by endoscopists performing ERCP
due to the lack of convincing scientific evidence [11].
Therefore, a larger sample meta-analysis should examine
the benefits of rectal indomethacin for PEP.
Methods
Literature search
We followed standard criteria for performing and
reporting a meta-analysis of RCT studies [12]. A system-
atic search of PubMed, EMBASE and the Cochrane
library (including CENTRAL) was performed to identify
potentially relevant publications (through June 2016).
Keywords included indomethacin, pancreatitis and
ERCP. The search was restricted to human studies, and
no language restrictions were set. In addition, the refer-
ence lists of all retrieved articles, as well as reviews and
abstracts from recent conferences, were manually
searched. When the same or similar patient studies were
included in several publications, only the most recent or
informative report was selected for analysis.
Study selection
Studies were initially selected based on their titles and
abstracts. Two reviewers (JH.W. and YP.R.) independ-
ently screened all abstracts to determine whether the
studies met the inclusion criteria. Differences were
resolved by a third investigator (L.X.). Studies were con-
sidered eligible if they met the following criteria: (1)
studies that examined the efficacy and safety of prophy-
lactic rectal indomethacin use for PEP; (2) studies that
were prospective and randomized; (3) studies in humans;
and (4) data that were not duplicated in another article.
Studies were excluded if (1) the study design was retro-
spective or the study was not an RCT or (2) unadjusted
estimates were reported.
Data abstraction and quality assessment
To ensure homogeneity in data gathering and entry, the
data extraction was conducted by two experienced inves-
tigators working independently (JH.W. and YP.R.). A
third investigator (L.X.) was called upon to resolve any
differences so that complete consensus was reached for
all of the main variables to be assessed in the analysis.
Data were recorded as follows: the first author’s last
name (year of publication), country, setting, study de-
sign, size of the trial, outcomes, intervention, inclusion
criteria, exclusion criteria, definition of PEP, complica-
tions and study quality (recorded in Table 1). The quality
of the included studies was assessed independently by
two reviewers (JH.W. and YP.R.) using the Cochrane
Collaboration tool for assessing the risk of bias [13]
(Additional file 1 Figure S1). The grading system con-
tains the following criteria: random sequence generation,
allocation concealment, blinding of participants and
personnel, blinding of outcome assessment, incomplete
outcome data, selective reporting and other bias. Each
trial was given an overall summary assessment of low,
unclear, or high-risk of bias.
Statistical analysis
Statistical analysis of the Relative Risk (RR) with the 95%
confidence interval (CI) was used as a common measure
of the association between rectal indomethacin and PEP
across studies. Taking both within-study and between-
study variabilities into account, we used a random-effects
model, which is more conservative than a fixed-effects
model, to aggregate data and obtain the overall effect size
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and 95% CI. Heterogeneity across studies was assessed by
performing X2 tests (assessing the P value) and calculating
I2, which is a quantitative measure of inconsistency across
studies. Studies with an I2 of 25 to 50% were considered
to have low heterogeneity; studies with an I2 of 50to 75%
were considered to have moderate heterogeneity; and
studies with an I2 > 75% were considered to have high het-
erogeneity. If I2 > 50%, potential sources of heterogeneity
were identified by sensitivity analyses conducted by omit-
ting one study at a time and investigating the influence of
a single study on the overall pooled estimate. Publication
bias was examined by Egger’s test and Begg’s test. All
calculations were conducted with Review Manager V 5.0
software (provided by the Cochrane Collaboration,
Oxford, UK) and Stata version 12.0 (Stata Corporation,
College Station, TX, USA). All P values were two-sided,
and the significance level was 0.05.
Results
Identification of eligible studies
Based on our search criteria, we identified 332 papers
from MEDLINE/PubMed, EMBASE and the Cochrane
Central Register of Controlled Trials in the Cochrane
Table 1 Characteristics of Studies Included in Meta-analysis
Study Year Location Indomethacin (n) Placebo (n) Number of
PEPs (n)
Intervention Definition of PEP
Montaño Loza et al. 2007 Mexico 75 75 16 100 mg indomethacin
2 h before ERCP
Pain, Amylase > 3 times
Sotoudehmane sh et al. 2007 Iran-Single centre 245 245 22 100 mg indomethacin
immediately before ERCP
Pain, Amylase > 3 times
admission
Elmunzer et al. 2012 US-Multicentre 295 307 79 two 50-mg indomethacin
after ERCP
Pain, Amylase > 3 times
admission > 2 nigh
döbrönte et al. 2014 Hungary-Multicentre 347 318 42 100 mg indomethacin
10–15 min before ERCP
Pain, Amylase > 3 times
a prolognation of
admission, CT/MRI
Andrade-Dávila et al. 2015 Mexico 82 84 21 100 mg indomenthacin
after ERCP
Pain, Amylase > 3 times
admission > 2 nigh
Patai et al. 2015 USA-Single centre 270 296 55 100 mg indomethacin
within 1 before ERCP
Pain, Amylase > 3 times
Levenick et al. 2016 USA-Single centre 223 226 27 two 50-mg indomethacin
during ERCP
Pain, Amylase > 3 times
admission > 2 nigh
Fig. 1 Identification of eligible studies from different databases
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Library. Of these articles, 167 duplicate articles were
removed. Of those articles, the majority were
excluded after reviewing titles and abstracts, mainly
because they were reviews, letters, comments, retro-
spective studies or not relevant to our analysis, leav-
ing 64 papers that appeared to meet our selection
criteria. Of those papers, 21 were excluded because
they were reviews or meta-analyses; 11 were excluded
for irrelevance or were duplicate studies; 4 studies
were excluded because they were non-RCTs and 21
papers were excluded because they were comments or
letters to the editor. Finally, a total of 7 RCTs with
3013 participants were included in the meta-analysis
[10, 14–19]. A detailed flowchart of the selection
process is shown in Fig. 1.
Study characteristics
The main characteristics of the studies in the meta-
analysis are presented in Table 1. These studies were
published between 2007 and 2016. Among the 7 studies,
3 were conducted in America [10, 15, 16], 2 studies were
conducted in Mexico [14, 19] and the remaining 2 stud-
ies were conducted in Hungary [18] and Iran [17]. All
studies were published in English language journals. All
studies used a total dose of 100 mg of rectal indometh-
acin, but included pre-ERCP and post-ERCP administra-
tion. Two studies selected patients with an elevated
baseline risk of PEP.
Main results
As the primary outcome, the incidence of PEP was mea-
sured in all 7 studies. The RR was evaluated between
rectal indomethacin and a placebo for the prevention of
PEP. The Mantel-Haenszel pooled RR for PEP after
prophylactic administration of rectal indomethacin com-
pared to the placebo was 0.58 (95% CI, 0.40–0.83; P =
0.004; Fig. 2), corresponding to an absolute risk reduc-
tion of 4.8 percentage points (number needed to treat
[NNT] to prevent one episode of post-ERCP pancreatitis
was 21) and a relative risk reduction of 43%. Statistically,
heterogeneity was observed (I2 = 50%; P = 0.06), which
may have occurred due to the following three factors:
two studies selected patients with an elevated baseline
risk of PEP, two studies used the prophylactic placement
of pancreatic stents for most of the patients, and the
timing of administration of rectal indomethacin differed
among the studies. Therefore, the random effects model
was used.
Subgroup analyses
In our subgroup analysis by severity of PEP, 7 studies
(n = 3013; weight, 74.5%) using rectal indomethacin
for the prevention of mild PEP showed a significant
difference (RR, 0.61; 95% CI, 0.40–0.93; P = 0.02), and
similarly, 6 studies (n = 3013; weight, 25.5%) using
rectal indomethacin for prevention of moderate-to-
severe PEP showed a significant benefit (RR, 0.53;
95% CI, 0.31–0.88; P = 0.01) (Fig. 3 and 4). In
Fig. 2 Forest plot of the overall rate of PEP treatment with rectal indomethacin
Fig. 3 Forest plot of mild vs. moderate-to-severe PEP treated with rectal indomethacin
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summary, rectal indomethacin can reduce the inci-
dence of mild and moderate-to-severe PEP.
When comparing patients at average risk and high
risk for PEP, rectal indomethacin showed a significant
overall reduction in the incidence of PEP only in the
high-risk patients (3 studies with 1161 patients;
weight, 45.3%) (RR, 0.46; 95% CI, 0.32–0.65; P <
0.00001), whereas pooled data from 5 studies (n =
1852; weight, 54.7%) involving patients at average risk
for PEP showed that rectal indomethacin had no signifi-
cant benefit (RR, 0.75; 95% CI, 0.46–1.22; P = 0.25) (Fig. 5).
The NNT to prevent 1 episode of PEP in the high-risk
patient group was 10.
In the subgroup analysis of the timing of administra-
tion of rectal indomethacin, pooled data from 4 studies
(n = 1796; weight, 55.8%) in which rectal indomethacin
was administered before ERCP showed a statistically
significant difference in the occurrence of PEP related to
this timing (RR, 0.56; 95% CI, 0.39–0.79; P = 0.001).
However, 3 studies (n =1217; weight, 44.2%) in which
rectal indomethacin was administered after the
procedure showed no significant benefit (RR, 0.61; 95%
CI, 0.26–1.44; P = 0.26) for PEP prophylaxis (Fig. 6).
Only four studies reported bleeding as an adverse
event that was potentially related to indomethacin. The
results showed no statistical significance between the
two groups (RR, 0.97; 95% CI, 0.44–2.12; P = 0.94)
(Fig. 7).
Sensitivity Analysis
When a single study involved in the meta-analysis was
deleted each time, the results of meta-analysis remained
unchanged, indicating that the results of the present
meta-analysis were stable.
Publication bias
A funnel plot showed that the studies were reasonably
well scattered (Fig. 8). There was no statistical evidence
of publication bias among studies by using both Egger’s
regression asymmetry test (P = 0.61) (Additional file 2
Figure S2) and the Begg’s adjusted rank correlation
(P = 0.37) (Additional file 3 Figure S3).
Fig. 4 Forest plot of mild vs. moderate-to-severe PEP treated with rectal indomethacin
Fig. 5 Forest plot of patients at average risk vs. high risk for PEP treated with rectal indomethacin
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Discussion
In this meta-analysis, we found that rectal indomethacin
is generally more effective than a placebo for preventing
PEP in patients undergoing ERCP. It reduces the inci-
dence of PEP by nearly 43%, with an NNT of approxi-
mately 22 subjects. However, some studies included
patients of different classification, leading to the pres-
ence of clinical heterogeneity. Therefore, this result is
not very persuasive. Previous meta-analyses all con-
cluded that rectal indomethacin was superior to a
placebo for preventing PEP in both average- and high-
risk patients undergoing ERCP [7, 20–28]. However,
those meta-analyses included only a small number of
patients who used indomethacin, which reduces the pre-
cision of the comparative results, and their conclusions
were limited. Three of those meta-analyses included only
3 or 4 studies [20, 21, 23]. Another meta-analysis in-
cluded indomethacin and other NSAIDs, such as diclofe-
nac, or other routes of administration [7, 22, 24–28].
Compared to the results of previous meta-analyses, the
results of the present meta-analysis included more re-
cent RCTs that were different from the RCTs included
in the previous analyses. In our subgroup analysis of
average- and high-risk patients, rectal indomethacin was
not effective in patients at average risk for PEP. Recently,
an RCT from a single center showed that prophylactic
rectal indomethacin did not reduce the incidence or se-
verity of PEP in consecutive patients undergoing ERCP
[10]. In this study, patients were deliberately not catego-
rized into high- and low-risk groups for PEP. Hence,
rectal indomethacin should be applied as the choice for
patients at high risk for PEP, considering its effective-
ness, economy and side effects. Similarly, Elmunzer et al.
[15] showed that two 50-mg doses of rectal indometh-
acin significantly reduced the risk of PEP from 16.9% in
those receiving the placebo to 9.2% in those receiving
indomethacin for patients at high risk for PEP, including
82.3% of patients who had a clinical suspicion of SOD
dysfunction. It should be noted that in this study, the
authors placed a pancreatic stent in 246 patients in the
indomethacin group (83.4%) and in 250 individuals in
the placebo group (81.4%).
In our subgroup analysis of post-ERCP and pre-ERCP
prophylactic administration, rectal indomethacin was
Fig. 6 Forest plot of the timing of administration of rectal indomethacin for PEP
Fig. 7 Forest plot of bleeding as an adverse clinical event in the treatment of PEP using rectal indomethacin
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not effective in patients when administered post-ERCP.
Previous research has found that the peak plasma con-
centration of indomethacin is reached 30 min after rec-
tal administration, when bioavailability is complete [29].
The elimination half-life of indomethacin is 4.5 h. When
the drug was used before ERCP, the peak level was
achieved at the desirable time. Theoretically, therefore,
rectal indomethacin may be more effective before the
ERCP than after the procedure. A meta-analysis by
Rustagi et al. [7] in 2014 found that NSAID adminis-
tration before ERCP had a greater benefit than ad-
ministration after the procedure. Recently, Luo et al.
found that the strategy of prophylactic pre-ERCP ad-
ministration of rectal indomethacin for all patients
was superior to the strategy of purposeful rectal indo-
methacin after ERCP in only high-risk patients for
reducing the risk of PEP [30]. Therefore, the timing
of administration of rectal indomethacin should be
before rather than after ERCP.
Of note, no differences in adverse events potentially
attributable to rectal indomethacin treatment were ob-
served, suggesting that indomethacin is a safe pharmaco-
logic agent for the prevention of PEP. Four studies
reported bleeding as an adverse event, but statistical
significance was not achieved. Three patients died from
severe PEP in 3 studies, all of which occurred in the pla-
cebo group. Other adverse events also occurred in these
3 studies.
The present meta-analysis has some limitations. First,
low-quality and small number of studies were included.
Second, this meta-analysis exhibits statistical homogen-
eity. Andrade-Dávila et al. [19] and Elmunzer et al. [15]
enrolled only patients at high risk for PEP, whereas the
other 5 studies enrolled average-risk patients. Third,
studies differed in their definition of PEP and did not
always adhere to the Cotton criteria. Lastly, this meta-
analysis did not consider the influence of prophylactic
pancreatic stents. Patients in 2 studies underwent
prophylactic placement of pancreatic stents [10, 15].
In summary, this is the first meta-analysis to suggest
that rectal indomethacin is not suitable for all patients
undergoing ERCP and should be recommended for pre-
venting PEP in high-risk patients before ERCP. In
addition, larger multi-center RCTs are still needed to
determine the role of rectal indomethacin in low-risk
patients.
Conclusion
Although this meta-analysis indicates that prophylactic
rectal indomethacin is not suitable for all patients under-
going ERCP, it is safe and effective for the prevention of
PEP in high-risk patients. In addition, administration of
rectal indomethacin before ERCP is superior to adminis-
tration after ERCP for the prevention of PEP. In conclu-
sion, it is necessary to recommend rectal indomethacin
before ERCP for the prevention of PEP in high-risk
patients.
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